Skyran Biologics

Market/Category

  • Diabetic Retinopathy – Therapeutic

Principal Investigator(s) and Department

Clinical Problem

  • Diabetic retinopathy is caused by damage to the blood vessels at the back of the eye (retina) that can lead to blindness.
  • After 20 years of diabetes, nearly 99 percent of patients with Type 1 and 60 percent of those with Type 2 will have some form of Diabetic Retinopathy.
  • Most common course of treatment is monthly injections to the eye.

Therapeutic Solution

  • A novel patented PEDF (pigment epithelium-derived factor) derived peptide that has shown to have therapeutic effect in mouse and primate diabetic retinopathy models delivered via eye drops by reducing inflammation, cell death and vascular leakage.
  • Preliminary data indicates that these proprietary PEDF derived peptides could be a platform therapeutic for other ophthalmic degenerative diseases.